Systemic Mastocytosis (DBCOND0028386)

Identifiers

Synonyms
Mastocytosis, Systemic / Systemic mastocytosis / Systemic mastocytosis (morphologic abnormality) / Malignant systemic mastocytosis (morphologic abnormality) / Systemic mast cell disease (disorder) / Isolated bone marrow mastocytosis (disorder) / Smoldering systemic mastocytosis (morphologic abnormality) / Smoldering systemic mastocytosis (disorder) / Indolent Systemic Mastocytosis / Indolent systemic mastocytosis (morphologic abnormality) / Indolent systemic mastocytosis (disorder)

Associated Data

Indicated Drugs and Targets
DrugDescriptionTargets
Cimetidine
A histamine H2 receptor antagonist used to manage GERD, peptic ulcer disease, and indigestion.
Midostaurin
An antineoplastic agent used to treat high-risk acute myeloid leukemia (AML) with specific mutations, aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematologic neoplasm (SM-AHN), or mast cell leukemia (MCL).
Omeprazole
A proton pump inhibitor used to treat GERD associated conditions such as heartburn and gastric acid hypersecretion, and to promote healing of tissue damage and ulcers caused by gastric acid and H. pylori infection.
Ranitidine
A histamine H2 antagonist used to treat duodenal ulcers, Zollinger-Ellison syndrome, gastric ulcers, GERD, and erosive esophagitis.
Clinical Trials
IdentifierTitleDrug(s)PurposePhaseStatus
NCT06065007
Quality of Life and Disease-related Symptoms in Individuals With Systemic MastocytosisNo drug interventionsNot AvailableNot Availablerecruiting
NCT05186753
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosistreatment2recruiting
NCT04681105
Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignanciestreatment1active_not_recruiting
NCT00109707
A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignanciestreatment1 / 2completed
NCT00449748
Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosistreatment2completed
NCT00171912
Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymestreatment2completed
NCT01297777
Imatinib in KIT-negative Systemic Mastocytosistreatment4completed
NCT01807598
Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemiatreatment2completed
NCT03739606
Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancertreatment2withdrawn
NCT01334996
Use of Tamoxifen in Systemic MastocytosisNo drug interventionsNot AvailableNot Availablecompleted
NCT01602939
Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosistreatment2 / 3unknown_status
NCT02478957
Treatment of Indolent Systemic Mastocytosis With PA101No drug interventionstreatment2completed
NCT03214666
GTB-3550 Tri-Specific Killer Engager (TriKEĀ®) for High Risk Hematological Malignanciestreatment1 / 2terminated
NCT02441166
Diagnostic Value of Bone Marrow Tryptase in Systemic MastocytosisNo drug interventionsdiagnosticNot Availablecompleted
NCT00918931
Obatoclax for Systemic Mastocytosistreatment2terminated
NCT03401060
Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosistreatment3completed
NCT00979160
Evaluation of Response of Dasatinib to Treat Mastocytosistreatment2unknown_status
NCT00493129
Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM)treatment2completed
NCT02415608
Ibrutinib in Treating Patients With Advanced Systemic Mastocytosistreatment2terminated